Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3(rd)-line treatment

BACKGROUND: Somatostatin analogues are an established first-line therapy for well differentiated small bowel neuroendocrine tumours (Wd-SBNETs), while and peptide receptor radionuclide therapy (PRRT) is frequently used as a second-line therapy. Adequate treatment selection of third-line treatment re...

Descripción completa

Detalles Bibliográficos
Autores principales: Lamarca, Angela, Cives, Mauro, de Mestier, Louis, Crona, Joakim, Spada, Francesca, Öberg, Kjell, Pavel, Marianne, Alonso-Gordoa, Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Observational Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7968134/
https://www.ncbi.nlm.nih.gov/pubmed/33776367
http://dx.doi.org/10.3748/wjg.v27.i10.976

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7968134/
https://www.ncbi.nlm.nih.gov/pubmed/33776367
http://dx.doi.org/10.3748/wjg.v27.i10.976

Ejemplares similares